Hypermethylation of the cpg island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 Locus, occurs in a large percentage of human breast cancers

Cancer Research

Volumn 61, Issue 7, 2001, Pages 3105-3109

  Dammann, Reinhard ^a   Yang, Glen ^a   Pfeifer, Gerd P ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; RAS PROTEIN;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CPG ISLAND; GENE EXPRESSION; GENE LOCUS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN FAMILY; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 3; CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM PROTEINS; PROTEIN STRUCTURE, TERTIARY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0035300429     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Epidemiology, stage at diagnosis, and tumor biology of breast carcinoma in multiracial and multiethnic populations
2. BRCA1 and BRCA2: From molecular genetics to clinical medicine
3. The genetics of breast and ovarian cancer
4. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer
5. BRCA1 mutations in primary breast and ovarian carcinomas
6. Low incidence of BRCA2 mutations in breast carcinoma and other cancers
7. BRCA2 mutations in primary breast and ovarian cancers
8. Mutation analysis in the BRCA2 gene in primary breast cancers
9. Molecular genetics of breast cancer progression
10. Mutation and cancer: Statistical study of retinoblastoma
11. Alterations in DNA methylation: A fundamental aspect of neoplasia
12. Cancer epigenetics comes of age
13. Promoter-region hypermethylation and gene silencing in human cancer
14. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells
15. Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer
16. Distinct mechanisms of loss of estrogen receptor α gene expression in human breast cancer: Methylation of the gene and alteration of trans-acting factors
17. Methylation and silencing of the retinoic acid receptor-β2 gene in breast cancer
18. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas
19. Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic heterogeneous loss of E-cadherin expression during metastatic progression
20. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells
21. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: Correlation with disease characteristics
22. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors
23. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens
24. Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer
25. High frequency of hypermethylation at the 14-3-3 σ locus leads to gene silencing in breast cancer
26. Compromised HOXA5 function can limit p53 expression in human breast tumours
27. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers
28. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints
29. Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes
30. Accumulation of genetic alterations and progression of primary breast cancer
31. Loss of heterozygosity and p53 gene mutations in breast cancer
32. Detailed deletion mapping of chromosome arm 3p in breast cancers: A 2-cM region on 3p14.3-21.1 and a 5-cM region on 3p24.3-25.1 commonly deleted in tumors
33. Location of several putative genes possibly involved in human breast cancer progression
34. Comparative allelotyping of the short arm of human chromosome 3 in epithelial tumors of four different types
35. A genome-wide map showing common regions of loss of heterozygosity/allelic imbalance in breast cancer
36. Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene
37. Epigenetic inactivation of a RAS association domain family protein from the lung tumor suppressor locus 3p21.3
38. Status of breast cancer prognostication based on histopathologic data
39. High sensitivity mapping of methylated cytosines
40. COBRA: A sensitive and quantitative DNA methylation assay
41. Cellular differentiation, cytidine analogs, and DNA methylation
42. Aging and DNA methylation in colorectal mucosa and cancer
43. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis
44. Identification of Norel as a potential Ras effector
45. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
46. Microinjection of the ras oncogene protein into PC12 cells induces morphological differentiation
47. Ras signaling and apoptosis
48. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: Identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium